Artificial intelligence is creating new possibilities across health care, but in eye care, the conversation is becoming particularly interesting. The eye can provide clinicians with far more information than visual acuity alone, while advances in imaging, data analysis and research are opening new questions about what ocular information might reveal about a person’s broader health.
At the same time, challenges such as childhood myopia and unequal access to vision care are reinforcing a different point: innovation only matters when it can translate into better care for real patients. Those ideas will come together on September 25 at the SUNY College of Optometry Foundation’s inaugural Advancing Vision Summit in New York City.
Rather than focusing on a single clinical specialty or technology, the day-long program brings artificial intelligence, oculomics, myopia research, population health and community-based care into the same discussion. That combination makes the event worth watching because it reflects how much the conversation around vision care is expanding.
What Can the Eye Tell Us About Overall Health?
Eye care professionals have long understood that ocular findings can sometimes provide clues about health beyond vision. What is changing is the amount of information that can be captured and analyzed, along with the technology available to interpret it. That is where oculomics and artificial intelligence enter the picture.
The summit will open with Dr. David C. Rhew, Global Chief Medical Officer and Vice President of Health and Life Sciences at Microsoft, discussing “Healthcare from the Eye.” His session will explore how AI-enabled tools could be incorporated into care pathways to help identify health risks earlier and potentially reach larger patient populations.
The emphasis on care pathways matters because developing an algorithm is different from building a system in which useful information reaches the right clinician, leads to appropriate follow-up and ultimately benefits a patient. Questions about responsible AI, patient engagement, clinical coordination, partnerships and sustainable implementation are therefore just as important as what the technology itself can detect.
The summit's broader program reinforces that point. Dr. Rudrani Banik of the Icahn School of Medicine at Mount Sinai will examine ocular biomarkers and what clinicians may be able to observe before symptoms of systemic disease become apparent, while Dr. Dean VanNasdale of Ohio State University College of Optometry will look at vision through the wider lens of population data and health outcomes. Together, these discussions move the conversation from simply examining the eye to considering how ocular information might fit into a larger picture of health.
Myopia Shows Why Research and Clinical Care Need Each Other
Myopia provides another example of why the future of eye care cannot be viewed through a single lens. For clinicians working with children and families, myopia is an immediate care issue. For researchers, it remains an active area of investigation extending from basic biological mechanisms to clinical trials and patient outcomes.
SUNY's summit deliberately brings those perspectives together. Dr. Felicia Timmermann of CooperVision and Dr. Damaris Raymondi, founder of Sur Eye Care, will discuss collaborative approaches to childhood myopia management, placing the emphasis on how care is delivered and how professionals and families can work together around a child's vision.
Later in the program, the focus will move further upstream with a closing panel moderated by Dr. Lisa Ostrin, Dean for Graduate Studies and Research at SUNY College of Optometry. The session will examine the path from molecular and cellular discoveries to translational research, clinical trials and meaningful patient outcomes. Panelists include Dr. Alexandra Benavente-Perez, Dr. Xiaoying Zhu and L. Wayne Spencer.
That progression matters because scientific discoveries do not move directly from the laboratory into everyday clinical practice. Translational research provides the bridge, and clinical evidence is necessary to understand whether promising findings ultimately make a meaningful difference for patients. By including both myopia management and foundational research in the same program, the summit highlights the continuum between what clinicians can do now and the research that may shape what they can do in the future.
Innovation Is Also an Access Question
There is another side to conversations about AI and medical technology that can easily get overlooked: who will actually benefit? A sophisticated diagnostic or analytical tool has limited public-health value if the patients who could benefit from it have little access to eye care in the first place. That makes community health an essential part of any serious discussion about the future of vision care.
The Advancing Vision Summit addresses this directly through a session on Federally Qualified Health Centers and community health centers. Representatives from NYC Health + Hospitals, Lavelle Fund for the Blind and SUNY College of Optometry will explore how eye care can become more closely integrated with population-health strategies.
This is where the summit's technology and public-health themes begin to intersect. If ocular information can contribute to earlier identification of health risks, or if new technologies make certain forms of screening and analysis more scalable, then the settings in which patients receive care become increasingly important.
Community health centers could potentially provide a connection between advances developed in research or specialty care and populations that might otherwise encounter barriers to vision services. Technology may change what is possible, but health systems help determine how much of that possibility reaches patients.
Eye Care Is Becoming Part of a Bigger Health Conversation
The summit will also address women's eye health, medical technology and the role of artificial intelligence in public health. Taken together, these subjects point toward a broader change in how the profession thinks about vision.
Eye care remains fundamentally about helping people see and protecting ocular health. But the information available through the eye, the growth of large health datasets and advances in artificial intelligence are creating opportunities to connect vision care more closely with other areas of medicine and public health.
That does not mean every emerging technology will transform clinical practice. AI-enabled tools still need appropriate evidence, responsible implementation and clear clinical value. Research findings must survive the journey from laboratory discovery to clinical testing, while new models of care must work in the communities they are intended to serve.
Those are precisely the kinds of questions that become more useful when researchers, clinicians, technology leaders and public-health professionals are part of the same conversation. The SUNY College of Optometry Foundation is holding the inaugural Advancing Vision Summit as part of its 70th anniversary, with more than 150 clinicians, public-health leaders and community partners expected to attend the free event.
Its significance may ultimately be less about any one session than about the subjects SUNY has chosen to put alongside one another. AI, ocular biomarkers, childhood myopia, translational research and community access can look like separate areas of eye care, but increasingly they are connected by the same challenge: turning better information and better science into better health outcomes. That is a much bigger conversation than technology alone.
Sources
SUNY College of Optometry Foundation: “SUNY College of Optometry Foundation Features AI and Myopia Leaders at Inaugural Advancing Vision Summit on September 25”, September 14, 2026.
